Published in J Neuropsychiatry Clin Neurosci on January 01, 2008
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type. Psychiatry Res (2012) 0.94
Neural systems for cognitive and emotional processing in posttraumatic stress disorder. Front Psychol (2012) 0.82
Mismatch negativity in recent-onset and chronic schizophrenia: a current source density analysis. PLoS One (2014) 0.80
The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia (1971) 86.03
Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn Reson Med (1995) 21.06
Anterior cingulate cortex, error detection, and the online monitoring of performance. Science (1998) 10.91
Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry (2003) 10.07
Distracted and confused?: selective attention under load. Trends Cogn Sci (2005) 5.05
Schizophrenia: a disconnection syndrome? Clin Neurosci (1995) 4.69
Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry (2005) 4.31
Anterior cingulate cortex and response conflict: effects of frequency, inhibition and errors. Cereb Cortex (2001) 3.64
Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry (2001) 2.80
Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study. Am J Psychiatry (2001) 2.64
Dissociable prefrontal brain systems for attention and emotion. Proc Natl Acad Sci U S A (2002) 2.29
An event-related functional magnetic resonance imaging study of an auditory oddball task in schizophrenia. Schizophr Res (2001) 2.20
The effects of aging upon the hemodynamic response measured by functional MRI. Neuroimage (2001) 2.17
Generators of the late cognitive potentials in auditory and visual oddball tasks. Electroencephalogr Clin Neurophysiol (1998) 1.94
Differential contribution of frontal and temporal cortices to auditory change detection: fMRI and ERP results. Neuroimage (2002) 1.88
Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol Psychiatry (2005) 1.72
Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients. Lancet (1997) 1.70
Dysfunctional prefrontal regional specialization and compensation in schizophrenia. Am J Psychiatry (2006) 1.69
Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch Gen Psychiatry (2002) 1.66
White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry (2005) 1.56
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry (2005) 1.52
Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry (1995) 1.49
Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophr Res (2004) 1.45
Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res (2000) 1.44
Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry (2006) 1.34
Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry (2000) 1.34
Attention orienting dysfunction during salient novel stimulus processing in schizophrenia. Schizophr Res (2005) 1.27
Evidence for a refractory period in the hemodynamic response to visual stimuli as measured by MRI. Neuroimage (2000) 1.22
A functional magnetic resonance imaging study of auditory mismatch in schizophrenia. Am J Psychiatry (2001) 1.10
Latent inhibition in humans: data, theory, and implications for schizophrenia. Psychol Bull (1995) 1.08
ERPs in schizophrenia: effects of antipsychotic medication. Biol Psychiatry (1994) 1.08
P300 reduction and prolongation with illness duration in schizophrenia. Biol Psychiatry (2000) 1.08
Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. Biol Psychiatry (2001) 1.04
Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. Arch Gen Psychiatry (2004) 1.04
Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatry Res (2001) 1.04
Abnormal function of the brain system supporting motivated attention in medicated patients with schizophrenia: an fMRI study. Psychol Med (2006) 1.03
The spectrum of structural brain changes in schizophrenia: age of onset as a predictor of cognitive and clinical impairments and their cerebral correlates. Psychol Med (1989) 0.97
Frontal and temporal sources of mismatch negativity in healthy controls, patients at onset of schizophrenia in adolescence and others at 15 years after onset. Schizophr Res (2004) 0.96
Relationship of neuropsychological and MRI measures to age of onset of schizophrenia. Acta Psychiatr Scand (1998) 0.91
Graded visual attention modulates brain responses evoked by task-irrelevant auditory pitch changes. J Cogn Neurosci (2005) 0.90
Auditory attentional deficits in patients with schizophrenia. A positron emission tomography study. Arch Gen Psychiatry (1996) 0.88
Mismatch negativity responses in schizophrenia: a combined fMRI and whole-head MEG study. Am J Psychiatry (2004) 0.88
Impaired sensory processing in male patients with schizophrenia: a magnetoencephalographic study of auditory mismatch detection. Schizophr Res (1999) 0.87
A validation of event-related FMRI comparisons between users of cocaine, nicotine, or cannabis and control subjects. Am J Psychiatry (2006) 0.87
Functional magnetic resonance imaging measure of automatic and controlled auditory processing. Neuroreport (2005) 0.81
Relationship between auditory P300 amplitude and age of onset of schizophrenia in older patients. Psychiatry Res (1998) 0.80
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry (2005) 4.28
Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal (2004) 4.25
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry (2006) 3.28
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Test-retest and between-site reliability in a multicenter fMRI study. Hum Brain Mapp (2008) 2.63
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci (2007) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 2.52
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 2.32
Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study. Hum Brain Mapp (2009) 2.28
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 2.22
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res (2004) 2.06
Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. Psychiatr Serv (2009) 2.05
Teaching trainees to negotiate research collaborations with industry: a mentorship model. Am J Psychiatry (2010) 2.04
Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry (2005) 2.03
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. J Magn Reson Imaging (2012) 1.86
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 1.83
Components and correlates of family burden in schizophrenia. Psychiatr Serv (2006) 1.81
Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. Am J Psychiatry (2010) 1.79
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
Brain activity evoked by the perception of human walking: controlling for meaningful coherent motion. J Neurosci (2003) 1.68
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry (2005) 1.66
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry (2008) 1.62
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry (2012) 1.62
Neural correlates of impaired cognitive-behavioral flexibility in anorexia nervosa. Am J Psychiatry (2009) 1.59
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry (2004) 1.58
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res (2004) 1.56
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophr Res (2009) 1.54
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry (2005) 1.52
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry (2005) 1.52
Clozapine as a first treatment for schizophrenia. Am J Psychiatry (2003) 1.49
Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry (2008) 1.49
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry (2008) 1.49
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry (2010) 1.49
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res (2005) 1.48
The neural circuitry mediating shifts in behavioral response and cognitive set in autism. Biol Psychiatry (2007) 1.47
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) (2008) 1.46
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res (2002) 1.45
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
Our future is now. Am J Psychiatry (2014) 1.39
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology (2004) 1.38
Tuning in to the voices: a multisite FMRI study of auditory hallucinations. Schizophr Bull (2008) 1.38
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) (2004) 1.38
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry (2008) 1.37
Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry (2006) 1.34
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis (2006) 1.32
Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res (2005) 1.30
Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull (2008) 1.29
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res (2005) 1.28
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology (2009) 1.28
Do prolonged febrile seizures produce medial temporal sclerosis? Hypotheses, MRI evidence and unanswered questions. Prog Brain Res (2002) 1.26
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res (2006) 1.24
Social stimuli interfere with cognitive control in autism. Neuroimage (2007) 1.23
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol (2004) 1.23
Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res (2008) 1.23
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull (2007) 1.21
The benefit of directly comparing autism and schizophrenia for revealing mechanisms of social cognitive impairment. J Neurodev Disord (2010) 1.20
Science and recovery in schizophrenia. Psychiatr Serv (2008) 1.20
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res (2005) 1.20
Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex (2008) 1.20
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology (2010) 1.19
Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology. Schizophr Bull (2009) 1.19
Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry (2004) 1.18